Strecker and colleagues developed a tumor-specific delivery system using an adeno-associated virus (AAV vector, HER2-AAVaPD-1, to deliver an anti-PD-1 immunoadhesin (aPD-1) directly to tumor cells. This evidence concerns the gene ERBB2 and neoplasm.